Picture of AxoGen logo

AXGN — AxoGen News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

AxoGen Inc expected to post a loss of 7 cents a share - Earnings Preview

* AxoGen Inc  AXGN.OQ   AXGN.O  is expected to show a rise
in
quarterly revenue when it reports  results on May 2 for the
period ending March 31 2024
    * The Alachua Florida-based  company is expected to report a
14.5% increase in revenue to $41.964 million from $36.66 million
a year ago, according to the mean estimate from 6 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for AxoGen Inc is for a loss
of 7
cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for AxoGen Inc
is
$13.50​, above​ its last closing price of $6.66. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.12       -0.10      -0.06     Beat    37.8
 Sep. 30 2023  -0.05       -0.06      0.01      Beat    116
 Jun. 30 2023  -0.11       -0.13      -0.03     Beat    76.9​
 Mar. 31 2023  -0.15       -0.14      -0.10     Beat    31
 ​​Dec.        -0.11       -0.11      -0.03     Beat    73.6
 31 2022                                                
 Jan. 1 0001   -0.13       -0.12      -0.01     Beat    91.8​
 Jun. 30 2022  -0.14       -0.14      -0.06     Beat    58.6
 Mar. 31 2022  -0.16       -0.15      -0.20     Missed  -30.4
 This summary was machine generated April 30 at 14:12 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on AxoGen

See all news